Related Experiment Video

Updated: Jun 8, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Small-molecule inhibitors reveal a new function for Bcl-2 as a proangiogenic signaling molecule

Benjamin D Zeitlin1, Jacques E Nör

  • 1Department of Restorative Sciences, University of Michigan School of Dentistry, Ann Arbor, MI, USA.

Current Topics in Microbiology and Immunology
|October 14, 2010
PubMed

Insights

Small molecule inhibitors targeting the Bcl-2 family of proteins show promise as novel anti-cancer drugs. These inhibitors also exhibit potential anti-angiogenic properties, offering new therapeutic avenues.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cancer's complex etiology involves cellular pathways that evade treatment.
  • Bcl-2, a pro-survival protein, is a key target in cancer therapy.
  • Intersections of signaling pathways offer targets for novel anti-cancer drug development.

Purpose of the Study:

  • To review the efficacy, potency, and function of small molecule inhibitors targeting the Bcl-2 family.
  • To focus on compounds with substantial available literature data.
  • To discuss the anti-cancer and anti-angiogenic potential of these inhibitors.

Main Methods:

  • Literature review of small molecule inhibitors targeting the Bcl-2 family.
  • Analysis of efficacy, potency, and function data.
  • Examination of anti-cancer and anti-angiogenic effects.

Main Results:

  • Small molecule inhibitors targeting Bcl-2 proteins demonstrate significant anti-cancer activity.
  • These inhibitors exhibit varying degrees of efficacy and potency.
  • Emerging data suggests anti-angiogenic potential for this drug class.

Conclusions:

  • Small molecule Bcl-2 inhibitors represent a promising therapeutic strategy for cancer treatment.
  • Further research into their anti-angiogenic properties may reveal new clinical applications.
  • Targeting the Bcl-2 family offers a viable approach for novel drug development.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Examining BCL-2 Family Function with Large Unilamellar Vesicles08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...